Skip to main navigation
Skip to search
Skip to main content
Aston Research Explorer Home
Help & FAQ
Link opens in a new tab
Search content at Aston Research Explorer
Home
Research units
Profiles
Research Outputs
Datasets
Student theses
Activities
Press/Media
Prizes
Equipment
The future of new drugs for diabetes management
Clifford J. Bailey
, Caroline Day
School of Biosciences
Biosciences Research Group (BRG)
College of Health and Life Sciences
Aston Research Centre for Health in Ageing
Research output
:
Contribution to journal
›
Review article
›
peer-review
42
Link opens in a new tab
Citations (Scopus)
99
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The future of new drugs for diabetes management'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
A1 Receptor
50%
Albuminuria
25%
Cardiorenal
25%
Cardiorenal Syndrome
50%
Cardiovascular Outcome Trials
50%
Cardiovascular Safety
25%
Comorbidity
25%
Control Management
25%
Diabetes Management
100%
Dipeptidyl peptidase-4 (DPP-4)
25%
Effective Management
25%
Glomerular Filtration Rate
25%
Glucagon-like
50%
Glucose-lowering Drugs
50%
Glycemic Control
25%
Heart Failure Hospitalization
25%
High Cost
25%
Major Adverse Cardiovascular Events
25%
New Drugs
100%
Nonfatal Myocardial Infarction
25%
Outcome Trials
25%
Receptor Agonist
50%
Renal Parameters
25%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Type 2 Diabetes Mellitus (T2DM)
75%
Weight Management
25%
Medicine and Dentistry
Albuminuria
33%
Apoplexy
33%
Cardiovascular Disease
33%
Cardiovascular System
100%
Comorbidity
33%
Congestive Heart Failure
33%
Diabetes
100%
Dipeptidyl Peptidase-4 Inhibitor
33%
Glomerular Filtration Rate
33%
Glucagon-Like Peptide-1 Agonist
66%
Glycemic Control
33%
Health Care Cost
33%
Maturity Onset Diabetes of the Young
100%
Myocardial Infarction
33%
Nephropathy
66%
Sodium Glucose Cotransporter 2 Inhibitor
66%
Sodium-Glucose Cotransporter 2 Inhibitors
66%
Weight Management
33%
Pharmacology, Toxicology and Pharmaceutical Science
Albuminuria
33%
Cardiovascular Disease
33%
Cerebrovascular Accident
33%
Comorbidity
33%
Congestive Heart Failure
33%
Dipeptidyl Peptidase IV Inhibitor
33%
Glucagon Like Peptide 1 Receptor Agonist
66%
Heart Infarction
33%
Kidney Disease
66%
Maturity Onset Diabetes of the Young
100%
Sodium Glucose Cotransporter 2 Inhibitor
66%
sodium glucose cotransporter-2 inhibitors
66%